177 related articles for article (PubMed ID: 19111881)
21. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
22. Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer.
Bi J; Zhang Y; Malmrose PK; Losh HA; Newtson AM; Devor EJ; Thiel KW; Leslie KK
Cell Death Dis; 2022 Jan; 13(1):59. PubMed ID: 35039480
[TBL] [Abstract][Full Text] [Related]
23. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
24. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
25. HDACs and HDAC inhibitors in colon cancer.
Mariadason JM
Epigenetics; 2008; 3(1):28-37. PubMed ID: 18326939
[TBL] [Abstract][Full Text] [Related]
26. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
27. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.
Lin Z; Bazzaro M; Wang MC; Chan KC; Peng S; Roden RB
Clin Cancer Res; 2009 Jan; 15(2):570-7. PubMed ID: 19147762
[TBL] [Abstract][Full Text] [Related]
28. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
29. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions.
Tsai CH; Li CH; Liao PL; Chang YW; Cheng YW; Kang JJ
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118564. PubMed ID: 31672612
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
31. Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors.
Saunders LR; Verdin E
Mol Cancer Ther; 2006 Nov; 5(11):2777-85. PubMed ID: 17121924
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling.
Biçaku E; Marchion DC; Schmitt ML; Münster PN
Cancer Res; 2008 Mar; 68(5):1513-9. PubMed ID: 18316616
[TBL] [Abstract][Full Text] [Related]
33. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors and malignant melanoma.
Boyle GM; Martyn AC; Parsons PG
Pigment Cell Res; 2005 Jun; 18(3):160-6. PubMed ID: 15892712
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
38. A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress.
Chen YC; Huang WJ; Hsu JL; Yu CC; Wang WT; Guh JH
Prostate; 2013 Sep; 73(12):1270-80. PubMed ID: 23813634
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1).
Chen WY; Weng JH; Huang CC; Chung BC
Mol Cell Biol; 2007 Oct; 27(20):7284-90. PubMed ID: 17709382
[TBL] [Abstract][Full Text] [Related]
40. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]